|
| Reference | Year | Patients no. | Definitions of metabolic syndrome | Relative risk (RR) or odds ratios (OR) | P value |
|
Colorectal cancer |
Pelucchi et al. [24] | 2010 | 1378 | IDF criteria | Men: OR, 2.09 (95% CI, 1.38–3.18) | <0.001 |
>3 components | Women: OR, 1.15 (95% CI, 0.68–1.94) | P = 0.22 |
Ahmed et al. [25] | 2006 | 194 | ATP III | Men: RR, 1.78 ( 95% CI, 1.0–3.6) | |
>3 components or more | Women: RR, 1.16 ( 95% CI, 0.6–2.2) | |
Nonalcholic fatty liver disease |
Hamaguchi et al. [26] | 2005 | 816 | Presence of the metabolic syndrome | Men: OR, 4.00 (95% CI, 2.63–6.08) | <0.001 |
ATP III | Women: OR, 11.20 (95% CI, 4.85–25.87) | <0.001 |
liver fibrosis | Marchesini et al. [27] | 2003 | 304 | ATP III | OR, 3.5 (95% CI, 1.1–11.2) | P = 0.032 |
NASH | Marchesini et al. [27] | 2003 | 304 | ATP III | OR, 3.2 (95% CI, 1.2–8.9) | P = 0.26 |
Hepatocellular carcinoma (HCC) | Welzel et al. [28] | 2011 | 3649 | ATP III | OR, 2.13; (95% CI = 1.96–2.31) | P < 0.0001 |
Intrahepatic cholangiocarcinoma | Welzel et al. [28] | 2011 | 743 | ATP III | OR, 1.56; (95% CI = 1.32–1.83) | P < 0.0001 |
|